Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Nokia Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.72 (market cap $763.64M), while Nokia Corp trades at $10.34 (market cap $56.99B). The key difference: Nokia Corp is far larger — about 74.6× Ginkgo Bioworks Holdings Inc's market cap, and Nokia Corp pays a 1.61% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Nokia Corp for 66 Days on average.
| DNA | NOK | |
|---|---|---|
Market Cap | $763.64M | $56.99B |
Volume | 3,204,177 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $15.83 | $16.83 |
52-Week Low | $5.48 | $5.18 |
Typical Hold Time | 7 Days | 66 Days |
Enterprise Value | $865.59M | $55.01B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia for growth in AI and telecommunications infrastructure.
The outlook for Nokia is positive, supported by strong analyst consensus with a $17.50 price target and 61.5% buy ratings. Key opportunities include expanding AI and cloud orders, which grew 105% in Q2 2026. Risks involve competitive pressures in telecom equipment, reliance on global infrastructure spending, and volatility in net cash flow, which turned negative in 2025. Execution on partnerships and margin expansion are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
